A Phase 2 interventional study of MK-6194 and Placebo in Systemic Lupus Erythematosus, sponsored by Merck Sharp & Dohme LLC. Terminated at 127 sites in 17 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-10.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 266 studies in Lupus Erythematosus, Systemic with a site in China — 168 open to participants now, 191 under way, 22 of them phase 3. Lupus Erythematosus, Systemic · China.
Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, this one is the 57th largest by enrollment of the 245 interventional ones that give a count, is one of 24 that started in 2023, is one of 33 in phase 2, and was the 104th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →168 of the 266 studies in Lupus Erythematosus, Systemic with a site in China are open now. Recruiting first, the newest first:
Genentech, Inc. · Sites in China, Australia, Brazil and 3 more countries
Ages 18–75
Antengene Biologics Limited · Sites in China
Ages 18+
AstraZeneca · Sites in China, United States, Argentina and 32 more countries
Ages 5–80
AstraZeneca · Sites in China
Ages 18–70
Peking Union Medical College Hospital · Sites in China
Ages 6–18
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
266 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 128 · Phase 2 56 · Phase 3 36 · Phase 4 16
First in 2006; this study’s year is marked. 24 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 149 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 36 across the 245 interventional studies, 180 across the 21 observational. Of the 54 that completed or were terminated, 25 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
133 of 266 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Merck & Co., Inc has 2 studies filed under Lupus Erythematosus, Systemic — fewer than ten, so there is no comparison to draw.
58 of the studies in Lupus Erythematosus, Systemic with a site in China that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05843643Phase 3AbbVieProgram to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | 2027-03 |
| NCT05639114Phase 3Novartis PharmaceuticalsPhase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) | 2027-03-26 |
| NCT05126277Phase 3Novartis PharmaceuticalsSafety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | 2027-09-21 |
| NCT07657793Phase 3Chinese SLE Treatment And Research GroupSirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia | 2027-09-30 |
Add all 58 to your calendar (.ics) → With an account.
Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of MK-6194 in adult participants with systemic lupus erythematosus.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive subcutaneous (SC) MK-6194 3 mg every 2 weeks (q2w).
Biological: MK-6194
Participants receive SC MK-6194 3 mg every 4 weeks (q4w).
Biological: MK-6194
Participants receive SC placebo q2w.
Biological: Placebo
After completing 52 weeks of treatment with SC MK-6194 administered 3 mg q2w in the main study, participants continue to receive SC MK-6194 3 mg q2w in the extension period.
Biological: MK-6194
After completing 52 weeks of treatment with SC MK-6194 administered 3 mg q4w in the main study, participants continue to receive SC MK-6194 3 mg q4w in the extension period.
Biological: MK-6194
After completing 52 weeks of treatment with SC placebo administered q2w in the main study, participants are re-randomized to receive SC MK-6194 3 mg q2w in the extension period.
Biological: MK-6194 · Biological: Placebo
After completing 52 weeks of treatment with SC placebo administered q2w in the main study, participants are re-randomized to receive SC MK-6194 3 mg q4w in the extension period.
Biological: MK-6194 · Biological: Placebo
SC Injection
SC Injection
Number of Participants Achieving Systemic Lupus Erythematosus Responder Index (SRI-4) Response at Week 28
The SRI was a composite index used to assess clinical improvement in participants with SLE. The SRI-4 response evaluated global improvement, any significant worsening in unaffected organ systems, and improvements in disease activity, without compromise to the participant's overall condition. SRI-4 response was binary and either achieved or not achieved by the participant, thus there was no associated score. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of counts calculated as percentages was reported.
Time frame: Week 28
Number of Participants Who Experienced an Adverse Event (AE)
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs were reported based on study treatment received by the participant at time of event. The number of participants who experienced one or more AEs was reported.
Time frame: Up to approximately 16 months
Number of Participants Who Discontinued Study Treatment Due to an AE
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs were reported based on study treatment received by the participant at time of event. The number of participants who discontinued study treatment due to an AE was reported.
Time frame: Up to approximately 16 months
Number of Participants Achieving British Isles Lupus Assessment Group (BILAG)-Based Composite Lupus Assessment (BICLA) Response at Week 28
The BICLA response was a composite global measure of SLE disease activity. It distinguished between partial and complete improvement in all body systems. BICLA response was binary and either achieved or not achieved by the participant, thus there was no associated score. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of counts calculated as percentages was reported.
Time frame: Week 28
Number of Participants Achieving SRI-4 Response at Week 52
The SRI was a composite index used to assess clinical improvement in participants with SLE. The SRI-4 response evaluated global improvement, any significant worsening in unaffected organ systems, and improvements in disease activity, without compromise to the participant's overall condition. SRI-4 response was binary and either achieved or not achieved by the participant, thus there was no associated score. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of counts calculated as percentages was reported.
Time frame: Week 52
Number of Participants Achieving BICLA Response at Week 52
The BICLA response was a composite global measure of SLE disease activity. It distinguished between partial and complete improvement in all body systems. BICLA response was binary and either achieved or not achieved by the participant, thus there was no associated score. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of counts calculated as percentages was reported.
Time frame: Week 52
Number of Participants With a Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)-50 Response at Week 28
The CLASI-A score was used to evaluate lupus skin manifestations, with higher scores indicating increased disease severity and lower scores indicating less disease severity. CLASI-A scores of 0 to 9, 10 to 20, and 21 to 70 represented disease severity of mild, moderate, and severe, respectively. CLASI-50 was 50% improvement from baseline in the CLASI-A score. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of counts calculated as percentages was reported.
Time frame: Week 28
Number of Participants With a CLASI-50 Response at Week 52
The CLASI-A score was used to evaluate lupus skin manifestations, with higher scores indicating increased disease severity and lower scores indicating less disease severity. CLASI-A scores of 0 to 9, 10 to 20, and 21 to 70 represented disease severity of mild, moderate, and severe, respectively. CLASI-50 was 50% improvement from baseline in the CLASI-A score. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of counts calculated as percentages was reported.
Time frame: Week 52
Change From Baseline in Swollen Joint Count at Week 28
The joint count score was an evaluation of 28 joints in which joints were assessed for presence or absence of swelling. The number of affected joints could have ranged from 0 to 28; with higher values corresponding to higher disease activity and lower values to less disease activity. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations was reported.
Time frame: Baseline and Week 28
Change From Baseline in Swollen Joint Count at Week 52
The joint count score was an evaluation of 28 joints in which joints were assessed for presence or absence of swelling. The number of affected joints could have ranged from 0 to 28; with higher values corresponding to higher disease activity and lower values to less disease activity. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations was reported.
Time frame: Baseline and Week 52
Change From Baseline in Tender Joint Count at Week 28
The joint count score was an evaluation of 28 joints in which joints were assessed for presence or absence of tenderness. The number of affected joints could have ranged from 0 to 28; with higher values corresponding to higher disease activity and lower values to less disease activity. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations was reported.
Time frame: Baseline and Week 28
Change From Baseline in Tender Joint Count at Week 52
The joint count score was an evaluation of 28 joints in which joints were assessed for presence or absence of tenderness. The number of affected joints could have ranged from 0 to 28; with higher values corresponding to higher disease activity and lower values to less disease activity. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations was reported.
Time frame: Baseline and Week 52
Change From Baseline in Swollen and Tender Joint Count at Week 28
The joint count score was an evaluation of 28 joints in which joints were assessed for presence or absence of swelling and presence or absence of tenderness. The number of affected joints could have ranged from 0 to 28; with higher values corresponding to higher disease activity and lower values to less disease activity. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations was reported.
Time frame: Baseline and Week 28
Change From Baseline in Swollen and Tender Joint Count at Week 52
The joint count score was an evaluation of 28 joints in which joints were assessed for presence or absence of swelling and presence or absence of tenderness. The number of affected joints could have ranged from 0 to 28; with higher values corresponding to higher disease activity and lower values to less disease activity. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations was reported.
Time frame: Baseline and Week 52
Change From Baseline in Oral Corticosteroid Dose at Week 28
Participants were assessed for corticosteroid dose change. Oral corticosteroid dose was based on prednisone or prednisone-equivalent dose. The oral corticosteroid dose at Week 28 was determined by the visit window of Week 28 (±7 days). Missing Week 28 dose was imputed with 0 if the participant completed Week 28 efficacy assessments. Oral corticosteroid doses as the weighted average of all doses taken at Week 28, weighted by the number of days each oral corticosteroid dose was administered was reported. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations were reported.
Time frame: Baseline and Week 28
Change From Baseline in Oral Corticosteroid Dose at Week 52
Participants were assessed for corticosteroid dose change. Oral corticosteroid dose was based on prednisone or prednisone-equivalent dose. The oral corticosteroid dose at Week 52 was determined by the visit window of Week 52 (±7 days). Missing Week 52 dose was imputed with 0 if the participant completed Week 52 efficacy assessments. Oral corticosteroid doses as the weighted average of all doses taken at Week 52, weighted by the number of days each oral corticosteroid dose was administered was reported. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations were reported.
Time frame: Baseline and Week 52
Cumulative Oral Corticosteroid Use Between Week 0 and Week 28
Participants were assessed for cumulative oral corticosteroid dose. Oral corticosteroid dose was based on prednisone or prednisone-equivalent dose. The cumulative oral corticosteroid dose at Week 28, calculated from Week 0 (Day 1) to Week 28 was reported. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations were reported.
Time frame: Up to approximately 28 weeks
Cumulative Oral Corticosteroid Use Between Week 0 and Week 52
Participants were assessed for cumulative oral corticosteroid dose. Oral corticosteroid dose was based on prednisone or prednisone-equivalent dose. The cumulative oral corticosteroid dose at Week 52, calculated from Week 0 (Day 1) to Week 52 was reported. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations were reported.
Time frame: Up to approximately 52 weeks
Number of Participants Who Achieved Low Level of Disease Activity (LLDAS) at Week 28
LLDAS was a low disease activity state associated with significant protection against flares and organ damage accrual. It included both the measurement of disease activity and maintenance of immunosuppressive medications. LLDAS response was defined as hybrid SLEDAI ≤4 (with no activity in major organ systems), no new features of SLE activity compared with previous assessment, physician's global assessment (PGA) ≤1.0, current prednisone (or equivalent) dose ≤7.5 mg daily, and well-tolerated standard maintenance doses of immunosuppressive drugs and approved biological agents, excluding investigational drugs. LLDAS response was binary and was either achieved or not achieved by the participant, thus there was no associated score. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of counts calculated as percentages was reported.
Time frame: Week 28
Number of Participants Who Achieved LLDAS at Week 52
LLDAS was a low disease activity state associated with significant protection against flares and organ damage accrual. It included both the measurement of disease activity and maintenance of immunosuppressive medications. LLDAS response was defined as hybrid SLEDAI ≤4 (with no activity in major organ systems), no new features of SLE activity compared with previous assessment, physician's global assessment (PGA) ≤1.0, current prednisone (or equivalent) dose ≤7.5 mg daily, and well-tolerated standard maintenance doses of immunosuppressive drugs and approved biological agents, excluding investigational drugs. LLDAS response was binary and was either achieved or not achieved by the participant, thus there was no associated score. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of counts calculated as percentages was reported.
Time frame: Week 52
| Milestone | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo | MK-6194 3 mg Q2W (Main Study) / MK-6194 3 mg Q2W (Extension Period) | MK-6194 3 mg Q4W (Main Study) / MK-6194 3 mg Q4W (Extension Period) | Placebo (Main Study)/ MK-6194 3 mg Q2W (Extension Period) | Placebo (Main Study)/ MK-6194 3 mg Q4W (Extension Period) |
|---|---|---|---|---|---|---|---|
| Started | 49 | 49 | 51 | 0 | 0 | 0 | 0 |
| Treated | 49 | 49 | 51 | 0 | 0 | 0 | 0 |
| Completed | 2 | 4 | 6 | 0 | 0 | 0 | 0 |
| Not completed | 47 | 45 | 45 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 3 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 39 | 39 | 41 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 1 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 3 | 2 | 0 | 0 | 0 | 0 | 0 |
| Milestone | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo | MK-6194 3 mg Q2W (Main Study) / MK-6194 3 mg Q2W (Extension Period) | MK-6194 3 mg Q4W (Main Study) / MK-6194 3 mg Q4W (Extension Period) | Placebo (Main Study)/ MK-6194 3 mg Q2W (Extension Period) | Placebo (Main Study)/ MK-6194 3 mg Q4W (Extension Period) |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 2 | 4 | 2 | 4 |
| Treated | 0 | 0 | 0 | 2 | 4 | 2 | 4 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 2 | 4 | 2 | 4 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 2 | 4 | 2 | 4 |
The BICLA response was a composite global measure of SLE disease activity. It distinguished between partial and complete improvement in all body systems. BICLA response was binary and either achieved or not achieved by the participant, thus there was no associated score. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of counts calculated as percentages was reported.
| Participants | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo |
|---|---|---|---|
| Number of Participants Achieving British Isles Lupus Assessment Group (BILAG)-Based Composite Lupus Assessment (BICLA) Response at Week 28 | 12 | 6 | 6 |
The SRI was a composite index used to assess clinical improvement in participants with SLE. The SRI-4 response evaluated global improvement, any significant worsening in unaffected organ systems, and improvements in disease activity, without compromise to the participant's overall condition. SRI-4 response was binary and either achieved or not achieved by the participant, thus there was no associated score. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of counts calculated as percentages was reported.
| Participants | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo |
|---|---|---|---|
| Number of Participants Achieving SRI-4 Response at Week 52 | 3 | 4 | 4 |
The BICLA response was a composite global measure of SLE disease activity. It distinguished between partial and complete improvement in all body systems. BICLA response was binary and either achieved or not achieved by the participant, thus there was no associated score. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of counts calculated as percentages was reported.
| Participants | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo |
|---|---|---|---|
| Number of Participants Achieving BICLA Response at Week 52 | 3 | 2 | 4 |
The CLASI-A score was used to evaluate lupus skin manifestations, with higher scores indicating increased disease severity and lower scores indicating less disease severity. CLASI-A scores of 0 to 9, 10 to 20, and 21 to 70 represented disease severity of mild, moderate, and severe, respectively. CLASI-50 was 50% improvement from baseline in the CLASI-A score. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of counts calculated as percentages was reported.
| Participants | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo |
|---|---|---|---|
| Number of Participants With a Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)-50 Response at Week 28 | 4 | 2 | 0 |
The CLASI-A score was used to evaluate lupus skin manifestations, with higher scores indicating increased disease severity and lower scores indicating less disease severity. CLASI-A scores of 0 to 9, 10 to 20, and 21 to 70 represented disease severity of mild, moderate, and severe, respectively. CLASI-50 was 50% improvement from baseline in the CLASI-A score. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of counts calculated as percentages was reported.
| Participants | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo |
|---|---|---|---|
| Number of Participants With a CLASI-50 Response at Week 52 | 2 | 1 | 0 |
The joint count score was an evaluation of 28 joints in which joints were assessed for presence or absence of swelling. The number of affected joints could have ranged from 0 to 28; with higher values corresponding to higher disease activity and lower values to less disease activity. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations was reported.
| Score on a scale | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo |
|---|---|---|---|
| Change From Baseline in Swollen Joint Count at Week 28 | -6.9 ± 5.1 | -7.4 ± 4.6 | -5.6 ± 5.0 |
The joint count score was an evaluation of 28 joints in which joints were assessed for presence or absence of swelling. The number of affected joints could have ranged from 0 to 28; with higher values corresponding to higher disease activity and lower values to less disease activity. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations was reported.
| Score on a scale | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo |
|---|---|---|---|
| Change From Baseline in Swollen Joint Count at Week 52 | 1.3 ± 11.3 | -6.2 ± 3.3 | -5.9 ± 3.8 |
The joint count score was an evaluation of 28 joints in which joints were assessed for presence or absence of tenderness. The number of affected joints could have ranged from 0 to 28; with higher values corresponding to higher disease activity and lower values to less disease activity. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations was reported.
| Score on a scale | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo |
|---|---|---|---|
| Change From Baseline in Tender Joint Count at Week 28 | -10.8 ± 7.9 | -10.2 ± 6.7 | -9.4 ± 6.7 |
The joint count score was an evaluation of 28 joints in which joints were assessed for presence or absence of tenderness. The number of affected joints could have ranged from 0 to 28; with higher values corresponding to higher disease activity and lower values to less disease activity. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations was reported.
| Score on a scale | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo |
|---|---|---|---|
| Change From Baseline in Tender Joint Count at Week 52 | -1.8 ± 7.9 | -7.0 ± 3.8 | -9.6 ± 6.7 |
The joint count score was an evaluation of 28 joints in which joints were assessed for presence or absence of swelling and presence or absence of tenderness. The number of affected joints could have ranged from 0 to 28; with higher values corresponding to higher disease activity and lower values to less disease activity. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations was reported.
| Score on a scale | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo |
|---|---|---|---|
| Change From Baseline in Swollen and Tender Joint Count at Week 28 | -6.9 ± 5.2 | -7.4 ± 4.6 | -5.6 ± 5.0 |
The joint count score was an evaluation of 28 joints in which joints were assessed for presence or absence of swelling and presence or absence of tenderness. The number of affected joints could have ranged from 0 to 28; with higher values corresponding to higher disease activity and lower values to less disease activity. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations was reported.
| Score on a scale | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo |
|---|---|---|---|
| Change From Baseline in Swollen and Tender Joint Count at Week 52 | 1.3 ± 11.3 | -6.6 ± 3.6 | -5.9 ± 3.8 |
Participants were assessed for corticosteroid dose change. Oral corticosteroid dose was based on prednisone or prednisone-equivalent dose. The oral corticosteroid dose at Week 28 was determined by the visit window of Week 28 (±7 days). Missing Week 28 dose was imputed with 0 if the participant completed Week 28 efficacy assessments. Oral corticosteroid doses as the weighted average of all doses taken at Week 28, weighted by the number of days each oral corticosteroid dose was administered was reported. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations were reported.
| mg | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo |
|---|---|---|---|
| Change From Baseline in Oral Corticosteroid Dose at Week 28 | -3.5 ± 7.4 | -5.2 ± 5.0 | -4.2 ± 5.9 |
Participants were assessed for corticosteroid dose change. Oral corticosteroid dose was based on prednisone or prednisone-equivalent dose. The oral corticosteroid dose at Week 52 was determined by the visit window of Week 52 (±7 days). Missing Week 52 dose was imputed with 0 if the participant completed Week 52 efficacy assessments. Oral corticosteroid doses as the weighted average of all doses taken at Week 52, weighted by the number of days each oral corticosteroid dose was administered was reported. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations were reported.
| mg | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo |
|---|---|---|---|
| Change From Baseline in Oral Corticosteroid Dose at Week 52 | -5.5 ± 2.7 | -8.5 ± 7.4 | -8.3 ± 4.9 |
Participants were assessed for cumulative oral corticosteroid dose. Oral corticosteroid dose was based on prednisone or prednisone-equivalent dose. The cumulative oral corticosteroid dose at Week 28, calculated from Week 0 (Day 1) to Week 28 was reported. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations were reported.
| mg | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo |
|---|---|---|---|
| Cumulative Oral Corticosteroid Use Between Week 0 and Week 28 | 1509.3 ± 947.4 | 1540.8 ± 758.3 | 1622.7 ± 822.0 |
Participants were assessed for cumulative oral corticosteroid dose. Oral corticosteroid dose was based on prednisone or prednisone-equivalent dose. The cumulative oral corticosteroid dose at Week 52, calculated from Week 0 (Day 1) to Week 52 was reported. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations were reported.
| mg | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo |
|---|---|---|---|
| Cumulative Oral Corticosteroid Use Between Week 0 and Week 52 | 1355.6 ± 919.4 | 2268.1 ± 710.1 | 2047.5 ± 1089.3 |
LLDAS was a low disease activity state associated with significant protection against flares and organ damage accrual. It included both the measurement of disease activity and maintenance of immunosuppressive medications. LLDAS response was defined as hybrid SLEDAI ≤4 (with no activity in major organ systems), no new features of SLE activity compared with previous assessment, physician's global assessment (PGA) ≤1.0, current prednisone (or equivalent) dose ≤7.5 mg daily, and well-tolerated standard maintenance doses of immunosuppressive drugs and approved biological agents, excluding investigational drugs. LLDAS response was binary and was either achieved or not achieved by the participant, thus there was no associated score. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of counts calculated as percentages was reported.
| Participants | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo |
|---|---|---|---|
| Number of Participants Who Achieved Low Level of Disease Activity (LLDAS) at Week 28 | 4 | 2 | 2 |
The SRI was a composite index used to assess clinical improvement in participants with SLE. The SRI-4 response evaluated global improvement, any significant worsening in unaffected organ systems, and improvements in disease activity, without compromise to the participant's overall condition. SRI-4 response was binary and either achieved or not achieved by the participant, thus there was no associated score. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of counts calculated as percentages was reported.
| Participants | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo |
|---|---|---|---|
| Number of Participants Achieving Systemic Lupus Erythematosus Responder Index (SRI-4) Response at Week 28 | 15 | 9 | 10 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs were reported based on study treatment received by the participant at time of event. The number of participants who experienced one or more AEs was reported.
| Participants | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo | MK-6194 3 mg Q2W (Main Study) / MK-6194 3 mg Q2W (Extension Period) | MK-6194 3 mg Q4W (Main Study) / MK-6194 3 mg Q4W (Extension Period) | Placebo (Main Study)/ MK-6194 3 mg Q2W (Extension Period) | Placebo (Main Study)/ MK-6194 3 mg Q4W (Extension Period) |
|---|---|---|---|---|---|---|---|
| Number of Participants Who Experienced an Adverse Event (AE) | 38 | 38 | 35 | 1 | 1 | 0 | 1 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs were reported based on study treatment received by the participant at time of event. The number of participants who discontinued study treatment due to an AE was reported.
| Participants | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo | MK-6194 3 mg Q2W (Main Study) / MK-6194 3 mg Q2W (Extension Period) | MK-6194 3 mg Q4W (Main Study) / MK-6194 3 mg Q4W (Extension Period) | Placebo (Main Study)/ MK-6194 3 mg Q2W (Extension Period) | Placebo (Main Study)/ MK-6194 3 mg Q4W (Extension Period) |
|---|---|---|---|---|---|---|---|
| Number of Participants Who Discontinued Study Treatment Due to an AE | 4 | 6 | 1 | 0 | 0 | 0 | 0 |
LLDAS was a low disease activity state associated with significant protection against flares and organ damage accrual. It included both the measurement of disease activity and maintenance of immunosuppressive medications. LLDAS response was defined as hybrid SLEDAI ≤4 (with no activity in major organ systems), no new features of SLE activity compared with previous assessment, physician's global assessment (PGA) ≤1.0, current prednisone (or equivalent) dose ≤7.5 mg daily, and well-tolerated standard maintenance doses of immunosuppressive drugs and approved biological agents, excluding investigational drugs. LLDAS response was binary and was either achieved or not achieved by the participant, thus there was no associated score. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of counts calculated as percentages was reported.
| Participants | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo |
|---|---|---|---|
| Number of Participants Who Achieved LLDAS at Week 52 | 0 | 0 | 0 |
Collected over Up to approximately 19 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MK-6194 3 mg Q2W | 0/49 (0%) | 5/49 (10.2%) | 29/49 (59.2%) |
| MK-6194 3 mg Q4W | 0/49 (0%) | 5/49 (10.2%) | 25/49 (51%) |
| Placebo | 1/51 (2%) | 4/51 (7.8%) | 22/51 (43.1%) |
| MK-6194 3 mg Q2W (Main Study) / MK-6194 3 mg Q2W (Extension Period) | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| MK-6194 3 mg Q4W (Main Study) / MK-6194 3 mg Q4W (Extension Period) | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| Placebo (Main Study) / MK-6194 3 mg Q2W (Extension Period) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Placebo (Main Study) / MK-6194 3 mg Q4W (Extension Period) | 0/4 (0%) | 1/4 (25%) | 1/4 (25%) |
| Event | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo | MK-6194 3 mg Q2W (Main Study) / MK-6194 3 mg Q2W (Extension Period) | MK-6194 3 mg Q4W (Main Study) / MK-6194 3 mg Q4W (Extension Period) | Placebo (Main Study) / MK-6194 3 mg Q2W (Extension Period) | Placebo (Main Study) / MK-6194 3 mg Q4W (Extension Period) |
|---|---|---|---|---|---|---|---|
| HydronephrosisRenal and urinary disorders | 0/49 | 0/49 | 0/51 | 0/2 | 0/4 | 0/2 | 1/4 |
| AppendicitisInfections and infestations | 0/49 | 1/49 | 0/51 | 0/2 | 0/4 | 0/2 | 0/4 |
| BacteraemiaInfections and infestations | 1/49 | 0/49 | 0/51 | 0/2 | 0/4 | 0/2 | 0/4 |
| Gastroenteritis viralInfections and infestations | 1/49 | 0/49 | 0/51 | 0/2 | 0/4 | 0/2 | 0/4 |
| Herpes zosterInfections and infestations | 1/49 | 1/49 | 0/51 | 0/2 | 0/4 | 0/2 | 0/4 |
| PneumoniaInfections and infestations | 1/49 | 0/49 | 0/51 | 0/2 | 0/4 | 0/2 | 0/4 |
| PyelonephritisInfections and infestations | 0/49 | 1/49 | 0/51 | 0/2 | 0/4 | 0/2 | 0/4 |
| Respiratory tract infectionInfections and infestations | 0/49 | 1/49 | 0/51 | 0/2 | 0/4 | 0/2 | 0/4 |
| Upper respiratory tract infectionInfections and infestations | 0/49 | 1/49 | 0/51 | 0/2 | 0/4 | 0/2 | 0/4 |
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 1/49 | 0/49 | 0/51 | 0/2 | 0/4 | 0/2 | 0/4 |
| Event | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo | MK-6194 3 mg Q2W (Main Study) / MK-6194 3 mg Q2W (Extension Period) | MK-6194 3 mg Q4W (Main Study) / MK-6194 3 mg Q4W (Extension Period) | Placebo (Main Study) / MK-6194 3 mg Q2W (Extension Period) | Placebo (Main Study) / MK-6194 3 mg Q4W (Extension Period) |
|---|---|---|---|---|---|---|---|
| Muscle strainInjury, poisoning and procedural complications | 0/49 | 0/49 | 0/51 | 1/2 | 0/4 | 0/2 | 0/4 |
| FatigueGeneral disorders | 2/49 | 0/49 | 2/51 | 0/2 | 1/4 | 0/2 | 0/4 |
| Injection site reactionGeneral disorders | 6/49 | 2/49 | 0/51 | 0/2 | 0/4 | 0/2 | 1/4 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/49 | 0/49 | 2/51 | 0/2 | 1/4 | 0/2 | 0/4 |
| Upper respiratory tract infectionInfections and infestations | 8/49 | 5/49 | 2/51 | 0/2 | 0/4 | 0/2 | 0/4 |
| HeadacheNervous system disorders | 3/49 | 6/49 | 8/51 | 0/2 | 0/4 | 0/2 | 0/4 |
| Injection site erythemaGeneral disorders | 6/49 | 2/49 | 0/51 | 0/2 | 0/4 | 0/2 | 0/4 |
| GastroenteritisInfections and infestations | 0/49 | 5/49 | 1/51 | 0/2 | 0/4 | 0/2 | 0/4 |
| Urinary tract infectionInfections and infestations | 5/49 | 2/49 | 1/51 | 0/2 | 0/4 | 0/2 | 0/4 |
| GastritisGastrointestinal disorders | 4/49 | 1/49 | 0/51 | 0/2 | 0/4 | 0/2 | 0/4 |
| Age, Continuous(Years) | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo | Total |
|---|---|---|---|---|
| Mean | 40.9 ± 13.8 | 40.4 ± 12.0 | 41.2 ± 14.0 | 40.8 ± 13.2 |
| Age, Customized(Participants) | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo | Total |
|---|---|---|---|---|
| Adults (Between 18 and 64 Years) | 48 | 48 | 49 | 145 |
| From 65 to 84 Years | 1 | 1 | 2 | 4 |
| Sex: Female, Male(Participants) | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo | Total |
|---|---|---|---|---|
| Female | 48 | 46 | 45 | 139 |
| Male | 1 | 3 | 6 | 10 |
| Ethnicity (NIH/OMB)(Participants) | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 29 | 25 | 29 | 83 |
| Not Hispanic or Latino | 20 | 24 | 22 | 66 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 15 | 10 | 12 | 37 |
| Asian | 8 | 13 | 15 | 36 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 |
| Black or African American | 4 | 3 | 0 | 7 |
| White | 20 | 21 | 20 | 61 |
| More than one race | 1 | 2 | 4 | 7 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Total Hybrid Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Score at Screening(Participants) | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo | Total |
|---|---|---|---|---|
| <10 | 27 | 27 | 29 | 83 |
| ≥10 | 22 | 22 | 22 | 66 |
| Oral Corticosteroid Dose (Prednisone or Equivalent) at Randomization(Participants) | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo | Total |
|---|---|---|---|---|
| <10 mg/day | 26 | 27 | 27 | 80 |
| ≥10 mg/day | 23 | 22 | 24 | 69 |
| Geographic Region(Participants) | MK-6194 3 mg Q2W | MK-6194 3 mg Q4W | Placebo | Total |
|---|---|---|---|---|
| Latin America/Eastern Europe | 24 | 24 | 26 | 74 |
| Rest of the World | 25 | 25 | 25 | 75 |
Showing the first 100 of 127 sites across 17 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Dec 2023 to primary completion in Jul 2025, 19 months.
Results were first posted in Aug 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MK-6194
Lupus Erythematosus, Systemic →